Shreyaskumar R Patel

List of Publications by Year
in descending order

134 papers	11,406 citations	71061 41 h-index	30058 103 g-index
139 all docs	139 docs citations	139 times ranked	10299 citing authors

#	Article	IF	Citations
1	Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. Journal of Clinical Oncology, 2007, 25, 1753-1759.	0.8	1,354
2	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 373, 1097-1104.	6.3	1,233
3	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 1493-1501.	5.1	921
4	Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. Journal of Clinical Oncology, 2007, 25, 2755-2763.	0.8	655
5	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology, 2016, 34, 786-793.	0.8	647
6	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2016, 387, 1629-1637.	6.3	610
7	Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 717-725.	1.8	336
8	A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors. Cancer Research, 2004, 64, 5913-5919.	0.4	334
9	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology, 2014, 32, 1563-1570.	0.8	252
10	Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation. Journal of Clinical Oncology, 2001, 19, 3483-3489.	0.8	234
11	Combination chemotherapy in adult desmoid tumors. Cancer, 1993, 72, 3244-3247.	2.0	225
12	Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib. Annals of Surgical Oncology, 2006, 14, 14-24.	0.7	220
13	Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer, 2011, 117, 4939-4947.	2.0	212
14	Results of Two Consecutive Trials of Dose-Intensive Chemotherapy With Doxorubicin and Ifosfamide in Patients With Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 317-321.	0.6	187
15	Chemotherapy for soft tissue sarcoma. Cancer, 2016, 122, 2952-2960.	2.0	148
16	Immuno-genomic landscape of osteosarcoma. Nature Communications, 2020, 11, 1008.	5.8	143
17	Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extraâ€adrenal paragangliomas. Cancer, 2012, 118, 2804-2812.	2.0	128
18	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. Clinical Cancer Research, 2014, 20, 4200-4209.	3.2	127

#	Article	IF	Citations
19	A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer, 2003, 98, 2693-2699.	2.0	116
20	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
21	Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. European Journal of Cancer, 2014, 50, 1137-1147.	1.3	104
22	Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist, 2012, 17, 321-e329.	1.9	100
23	Myxoid liposarcoma. Experience with chemotherapy. Cancer, 1994, 74, 1265-1269.	2.0	97
24	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	2.0	96
25	A 15-year experience with chemotherapy of patients with paraganglioma. Cancer, 1995, 76, 1476-1480.	2.0	93
26	Radiation-induced sarcoma. Current Treatment Options in Oncology, 2000, 1, 258-261.	1.3	92
27	Pilot study of vitaxin?an angiogenesis inhibitor?in patients with advanced leiomyosarcomas. Cancer, 2001, 92, 1347-1348.	2.0	91
28	THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2014, 171, R111-R122.	1.9	91
29	Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity in Soft Tissue Sarcomas. Journal of Clinical Oncology, 2000, 18, 3378-3383.	0.8	84
30	SARC009: Phase 2 study of dasatinib in patients with previously treated, highâ€grade, advanced sarcoma. Cancer, 2016, 122, 868-874.	2.0	80
31	STUMP unâ€œstumpedâ€• anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. Journal of Hematology and Oncology, 2015, 8, 66.	6.9	75
32	Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment. Current Oncology Reports, 2018, 20, 13.	1.8	71
33	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer, 2018, 18, 913.	1.1	69
34	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clinical Cancer Research, 2018, 24, 4865-4873.	3.2	68
35	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist, 2018, 23, 62-70.	1.9	62
36	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clinical Sarcoma Research, 2017, 7, 11.	2.3	61

#	Article	IF	Citations
37	Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer, 2006, 107, 2881-2887.	2.0	60
38	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. Journal of Clinical Oncology, 2021, 39, 3128-3139.	0.8	56
39	Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway. Current Oncology Reports, 2013, 15, 386-395.	1.8	54
40	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecologic Oncology, 2017, 146, 531-537.	0.6	51
41	Overall survival and histologyâ€specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer, 2019, 125, 2610-2620.	2.0	47
42	Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Canadian Journal of Cardiology, 2017, 33, 1335.e13-1335.e15.	0.8	46
43	Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials. European Journal of Cancer, 2008, 44, 501-509.	1.3	44
44	Chemotherapy for Bone Sarcoma in Adults. Journal of Oncology Practice, 2016, 12, 208-216.	2.5	44
45	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	0.8	44
46	Should Patients with Highâ€Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy?. Oncologist, 2009, 14, 1003-1012.	1.9	40
47	Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunology, Immunotherapy, 2012, 61, 1113-1124.	2.0	39
48	A Systematic Review of Clinical Outcomes and Prognostic Factors for Patients Undergoing Surgery for Spinal Metastases Secondary to Breast Cancer. Global Spine Journal, 2016, 6, 482-496.	1.2	39
49	Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 860-870.	3.3	38
50	Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. , 1996, 78, 741-744.		37
51	Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemotherapy and Pharmacology, 2013, 72, 277-286.	1.1	37
52	Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028â€"A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 11006-11006.	0.8	37
53	Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist, 2018, 23, 360-366.	1.9	36
54	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist, 2019, 24, 110-116.	1.9	34

#	Article	IF	Citations
55	Primary Extraskeletal Osteosarcoma--Experience With Chemotherapy. Journal of the National Cancer Institute, 1995, 87, 1331-1333.	3.0	33
56	Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. Clinical Sarcoma Research, 2015, 5, 22.	2.3	33
57	The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Current Oncology Reports, 2017, 19, 78.	1.8	32
58	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. Journal of Clinical Oncology, 2017, 35, 11008-11008.	0.8	32
59	Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer, 2003, 97, 2848-2852.	2.0	31
60	Recent Developments in Salvage Chemotherapy for Patients with Metastatic Soft Tissue Sarcoma. Drugs, 2005, 65, 167-178.	4.9	31
61	Benign Tumors of the Spine. Spine, 2016, 41, S178-S185.	1.0	30
62	Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer, 2006, 107, 2237-2244.	2.0	29
63	Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer, 2017, 123, 3434-3440.	2.0	29
64	A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer, 2004, 101, 156-163.	2.0	27
65	Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience. Sarcoma, 2014, 2014, 1-6.	0.7	27
66	Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?. Clinical Orthopaedics and Related Research, 2015, 473, 3604-3611.	0.7	27
67	The role of revision surgery and adjuvant therapy following subtotal resection of osteosarcoma of the spine: a systematic review with meta-analysis. Journal of Neurosurgery: Spine, 2017, 27, 97-104.	0.9	27
68	Ewing Sarcoma of the Spine. Spine, 2018, 43, 622-629.	1.0	27
69	Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncology, 2018, 4, 814.	3.4	26
70	The challenge of the management of adolescents and young adults with soft tissue sarcomas. Pediatric Blood and Cancer, 2018, 65, e27013.	0.8	24
71	Navigating Risk Stratification Systems for the Management of Patients With GIST. Annals of Surgical Oncology, 2011, 18, 1698-1704.	0.7	23
72	Pediatric and Adult Osteosarcoma: Comparisons and Contrasts in Presentation and Therapy. Cancer Treatment and Research, 2009, 152, 355-363.	0.2	22

#	Article	IF	Citations
73	Phase II Study of Paclitaxel in Patients With Soft Tissue Sarcomas. Sarcoma, 1997, 1, 95-97.	0.7	21
74	Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surgical Oncology, 2000, 9, 67-70.	0.8	21
75	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports, 2017, 7, 15963.	1.6	21
76	Potential Combination Chemotherapy Approaches for Advanced Adult-Type Soft-Tissue Sarcoma. American Journal of Clinical Dermatology, 2008, 9, 207-217.	3.3	20
77	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444.	1.3	20
78	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist, 2017, 22, 1271-1277.	1.9	20
79	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers, 2019, 11, 677.	1.7	20
80	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers, 2020, 12, 1768.	1.7	20
81	Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treatment Reviews, 2012, 38, 467-472.	3.4	17
82	Phase 1 adaptive doseâ€finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with highâ€risk extremity and trunk soft tissue sarcoma. Cancer, 2015, 121, 3659-3667.	2.0	17
83	Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. Journal of Clinical Oncology, 2016, 34, 3680-3685.	0.8	17
84	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget, 2016, 7, 64421-64430.	0.8	17
85	PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma, 2020, 2020, 1-6.	0.7	16
86	An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer, 2021, 127, 2187-2195.	2.0	16
87	Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?. Journal of Computer Assisted Tomography, 2016, 40, 872-879.	0.5	15
88	Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Scientific Reports, 2017, 7, 9519.	1.6	15
89	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Molecular Cancer Therapeutics, 2020, 19, 1165-1172.	1.9	15
90	New chemotherapeutic strategies for soft tissue sarcomas. , 1999, 17, 47-51.		14

#	Article	IF	Citations
91	Chemotherapy for Bone Sarcomas in Adults: The MD Anderson Experience. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e656-e660.	1.8	13
92	Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?. Current Treatment Options in Oncology, 2017, 18, 34.	1.3	13
93	SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma, 2018, 2018, 1-9.	0.7	13
94	Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Investigational New Drugs, 1998, 16, 87-92.	1.2	12
95	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports, 2016, 6, 35448.	1.6	12
96	Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers, 2020, 12, 2927.	1.7	12
97	Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Research and Treatment, 2021, 186, 871-882.	1.1	12
98	Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Current Treatment Options in Oncology, 2003, 4, 433-439.	1.3	11
99	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer, 2019, 125, 4435-4441.	2.0	10
100	Effects of Darbepoetin Alfa Administered Once Per Cycle for the Prevention of Anemia on the Incidence of Transfusions, Neurocognitive Functions, and Symptom Assessment.. Blood, 2006, 108, 4232-4232.	0.6	10
101	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. Oncologist, 2021, 26, 250-260.	1.9	9
102	Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer, 2022, 128, 3383-3391.	2.0	9
103	Realâ€world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer, 2021, 127, 1311-1317.	2.0	8
104	New agents in the treatment of soft-tissue sarcomas. Expert Opinion on Investigational Drugs, 2000, 9, 1545-1551.	1.9	7
105	Clinical Decision Making. Spine, 2016, 41, S171-S177.	1.0	7
106	Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma. Neurosurgery, 2021, 88, 428-436.	0.6	7
107	Systemic therapy for advanced soft-tissue sarcomas. Current Oncology Reports, 2002, 4, 299-304.	1.8	6
108	Recent advances in systemic therapy of soft tissue sarcomas. Expert Review of Anticancer Therapy, 2003, 3, 179-184.	1.1	6

#	Article	IF	Citations
109	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. Oncologist, 2020, 25, e1562-e1573.	1.9	6
110	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Medicine, 2021, 10, 3565-3574.	1.3	6
111	Recent Studies in Novel Therapy for Metastatic Sarcomas. Hematology/Oncology Clinics of North America, 2005, 19, 573-590.	0.9	5
112	An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Current Oncology Reports, 2016, 18, 49.	1.8	5
113	Molecular Imaging with 3â€²-deoxy-3â€²[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics, 2020, 10, 125.	1.3	5
114	Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. Journal of Adolescent and Young Adult Oncology, 2021, , .	0.7	5
115	Interleukin-6, Hepcidin, and Other Biomarkers in Anemia of Chronic Disease (ACD) and Chemotherapy-Induced Anemia (CIA): Potential Therapeutic Targets.. Blood, 2012, 120, 2086-2086.	0.6	5
116	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. Journal of Clinical Oncology, 2016, 34, 11061-11061.	0.8	5
117	Fifty Years of Advances in Sarcoma Treatment: Moving the Needle from Conventional Chemotherapy to Targeted Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 259-262.	1.8	4
118	Predictors of survival in patients with sarcoma admitted to the intensive care unit. Clinical Sarcoma Research, 2016, 6, 12.	2.3	4
119	Myxoid liposarcoma. Experience with chemotherapy. , 1994, 74, 1265.		4
120	Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. Sarcoma, 2017, 2017, 1-6.	0.7	3
121	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. Journal of Clinical Oncology, 2017, 35, 60-60.	0.8	3
122	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. OncoTargets and Therapy, 2021, Volume 14, 3037-3049.	1.0	2
123	Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas. Expert Opinion on Investigational Drugs, 2002, 11, 1789-1793.	1.9	1
124	Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (Pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy.. Journal of Clinical Oncology, 2016, 34, 11060-11060.	0.8	1
125	Preface. Cancer Chemotherapy and Pharmacology, 2011, 67, 1-1.	1.1	0
126	Primary Retroperitoneal Tumors. , 2012, , 403-421.		0

#	Article	IF	Citations
127	Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series.. Journal of Clinical Oncology, 2016, 34, 11069-11069.	0.8	0
128	Clinical next-generation sequencing in sarcomas.. Journal of Clinical Oncology, 2016, 34, 11046-11046.	0.8	0
129	Increase in the patient wait-time and delays in the clinic workflow post-implementation of the electronic health record.. Journal of Clinical Oncology, 2017, 35, 194-194.	0.8	0
130	Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations.. Journal of Clinical Oncology, 2017, 35, 11019-11019.	0.8	0
131	Impact of room pooling and electronic health record on patient (pt) wait time, clinic work flow, and ptsâ€™/providersâ€™ satisfaction.. Journal of Clinical Oncology, 2017, 35, e18191-e18191.	0.8	0
132	Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.. Journal of Clinical Oncology, 2018, 36, 10520-10520.	0.8	0
133	Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.. Journal of Clinical Oncology, 2018, 36, 11522-11522.	0.8	0
134	Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).. Journal of Clinical Oncology, 2018, 36, 11513-11513.	0.8	0